Expired activity
Please go to the PowerPak
homepage and select a course.
Undiagnosed Non-Valvular Atrial Fibrillation: A Pharmacist’s Guide to Improving Identification and Management for Stroke Prevention
A Virtual Midday Symposium conducted at the 2021 ASHP Virtual Midyear Clinical Meeting and Exhibition
This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Bristol Myers Squibb and the Pfizer Alliance.
Registration & Dates for Activities
Tuesday, December 7, 2021
1:00 PM to 2:30 PM
Click Here
There is no fee for this educational activity.
FACULTY
Brian T. Cryder, PharmD, BCACP
Associate Professor of Pharmacy Practice
Midwestern University College of Pharmacy
Downers Grove, IL
Clinical Pharmacists
Advocate Medical Group
Chicago, IL
FINANCIAL DISCLOSURE
Dr. Trujillo has disclosed that she has served as a consultant for Sanofi and Novo Nordisk, Inc.
Dr. Whitley has disclosed that she has served as a consultant for the Medication Information Institute.
The patients participating in this program have no relevant financial relationships to disclose.
The clinical reviewer, Susan Cornell, BS, PharmD, CDCES, FAPhA, FADCES has disclosed that she has received fees for consulting and non-CME services from Novo Nordisk, Inc.
Susanne Batesko, RN, BSN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
ACCREDITATION STATEMENTS
PHARMACY
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-21-088-L01-P
Credits: 1.5 hour (0.15 ceu)
Type of Activity: Application
Media: Internet
Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 90 minutes
TARGET AUDIENCE
Health-system pharmacists and other pharmacists who may manage patients with undiagnosed Non-Valvular Atrial Fibrillation (NVAF).
HOW TO EARN CREDIT
Participants must 1) read the learning objectives and faculty disclosures; 2) attend and participate in the virtual symposium; and 3) complete the posttest and evaluation form directly after the event with a maximum of within 60 days of attending the live session. To answer the questions, click on your selected choice for each answer then proceed to the next question. Your credit will automatically uploaded to CPE Monitor.
Overview
Stroke is currently the leading cause of serious long-term disability in the US, and the underuse of anticoagulation in atrial fibrillation (AF) has been recognized as a global problem that may be contributing to increased stroke occurrence. National guidelines for the management of non-valvular AF (NVAF), which is the most common type of AF, now recommend direct-acting oral anticoagulants (DOACs) over warfarin in patients who are eligible for oral anticoagulation for stroke prevention. There are many factors to consider when choosing an anticoagulant in this population, and making evidence-based, patient-specific decisions in this arena can be challenging. Stroke risk, bleeding risk, dosing regimen/ease of adherence, drug interactions, and patient comorbidities may all play a role in the anticoagulant selection process. This interactive symposium will provide the latest science on the consequences of undiagnosed/untreated NVAF, identification strategies and risk factors, and considerations for anticoagulant selection to ensure early and appropriate treatment for optimal stroke prevention.
LEARNING OBJECTIVES
Upon completion of this program, participants should be better able to:
- Explain the implications of undiagnosed/untreated NVAF and discuss the various types of screening methods for AF
- Discuss principles of stroke prevention in newly diagnosed NVAF
- Compare pharmacological characteristics, efficacy, and safety profiles of oral anticoagulants used for stroke prevention in NVAF
- Formulate individualized, evidence-based anticoagulation plans for newly diagnosed/previously untreated patients with NVAF using a shared decision-making process
Agenda
Introduction (5 minutes)
Presentation (75 minutes)
Conclusions & Question & Answer Session (10 minutes)
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
Disclosure of Unlabeled Use and Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, or Novo Nordisk, Inc. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.